Compare Summit Therapeutics Inc (SMMT) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs VF Corp — how do they compare? Summit Therapeutics Inc trades at $15.26 (market cap $12.06B), while VF Corp trades at $14.65 (market cap $5.81B). The key difference: Summit Therapeutics Inc is far larger — about 2.1× VF Corp's market cap, and VF Corp pays a 2.44% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | VFC | |
|---|---|---|
Market Cap | $12.06B | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.98 | $21.55 |
52-Week Low | $12.55 | $12.21 |
Enterprise Value | $11.39B | $10.09B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
VFC trades at $14.70, down 1.34% over 24 hours, with a bearish technical signal and neutral oscillators. Recent earnings showed a Q2 2026 miss with a loss of $0.27 per share versus a $0.22 loss expected, though Q4 2025 beat expectations. Revenue declined to $9.50 billion in 2025, with a net loss of $189.72 million, while the company maintains a gross margin of 54.97%. Deleveraging progress continues, but Vans brand performance remains a headwind.
The outlook is mixed; analyst consensus is a 'Hold' with a $17.44 price target, implying potential upside. Risks include persistent Vans weakness, macroeconomic pressures, and competitive dynamics. Positive catalysts include raised fiscal 2027 revenue guidance and margin improvements, but execution on brand turnaround is critical for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
